rct-01
Cell therapyexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2015 (NCT02330146)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- VHL/BCR-ABL1Supplementation
VHL/BCR-ABL1 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02330146 | Phase 1/Phase 2 (Phase 2) | May 31, 2015 | Innovacell Biotechnologie AG, RepliCel Life Sciences, Inc., Syreon Corporation, University of British Columbia |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovacell Biotechnologie AG | For profit | 1 | 0 | 1 | 2015 |
| RepliCel Life Sciences, Inc. | For profit | 1 | 1 | 1 | 2015 |
| Syreon Corporation | For profit | 1 | 0 | 1 | 2015 |
| University of British Columbia | Academic/Hospital | 1 | 0 | 1 | 2015 |
4 organizations
Page 1 / 1